Views & Analysis We should quit Brexit, it's bad for our health Public health experts and UK life science leaders are reiterating concerns about Brexit’s threat to the nation’s health.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
